Pharmanovia licenses China-approved PARP drug for up to €423.5M
UK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million.
About Joachim Eeckhout
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 135 entries already.
Entries by Joachim Eeckhout
Relation deepens GSK alliance with $110M deal
London-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments.
Sanofi axes two more inflammatory-disease drugs
Sanofi has discontinued development of itepekimab and balinatunfib after disappointing clinical results, ending ongoing programmes across respiratory and inflammatory diseases.
Chiesi retreats from Gossamer PAH programme after Phase 3 miss
Italian pharmaceutical group Chiesi has returned all development and commercial rights to seralutinib to Gossamer Bio, ending a pulmonary arterial hypertension partnership originally valued at up to $486 million.
Fast-track trial approval: a way to jump the EU queue?
Launched in 2022, the EU Clinical Trials Information System (CTIS) aims to streamline and centralise the process of applying for clinical trial authorisation, but has also increased typical approval timelines. Several nations are now introducing accelerated pathways that jump the queue, offering one of the fastest routes to the clinic in the world for companies navigating this increasingly complex regulatory landscape.
argenx pays $2.2B for Forte’s early autoimmune promise
Belgian-Dutch immunology company argenx has agreed to acquire Forte Biosciences for $2.2 billion (€1.9 billion), gaining FB102, an early-stage antibody that has already produced efficacy signals in vitiligo and celiac disease.
CHMP backs Minoryx’s rare disease drug two years after rejection
Spanish biotech Minoryx Therapeutics has secured a positive European regulatory opinion for Nezglyal, two years after regulators rejected an earlier application for the rare neurodegenerative disease drug.
Sanofi drops eczema drug from $1.1B Kymab deal
Sanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments.
Iceland-based Synaptiq launches with Nobias’ rare disease drug
Newly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than three decades.
Fresenius launches €200M healthcare venture fund
German healthcare group Fresenius has created a corporate venture capital unit that plans to invest more than €200 million in healthcare startups over the next five years.